Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Farheen Chunara, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath V Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2024) 144 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2024-201599

Published: 2024

Journal Articles

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Alissa Visram, Rajshekhar Chakraborty, Gregory R Pond, Hsien Seow, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Samer Al Hadidi, Alejandro Garcia-Horton, Rafael Fonseca, Hira Mian

Blood (2024) 144 (Supplement 1): 5170.3.

https://doi.org/10.1182/blood-2024-200956

Published: 2024

Journal Articles

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Meghan Sise, Elizabeth Shelton, Emily Simone, Naomi Sender, Sherley Mejia, Shayan Shirazayan

Blood (2024) 144 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2024-210308

Published: 2024

Journal Articles

Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Katherine Berger, Ryan Winborg, Mason S. Barnes, Jorge Arturo Hurtado Martinez, Jay R. Hydren, Douglas W Sborov, Amandeep Godara, Brian McClune, Christopher Booth, Edward R Scheffer Cliff

Blood (2024) 144 (Supplement 1): 2281.

https://doi.org/10.1182/blood-2024-208803

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, J Christine Ye, Samuel M. Rubinstein, Sascha Tuchman, Eben I Lichtman

Blood (2024) 144 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2024-210587

Published: 2024

Journal Articles

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Juan Esteban Velez-Hernandez, Mateo Mejia Saldarriaga, Caitlin Unkenholz, Christian A Gordillo, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Markus Y Mapara, Ruben Niesvizky, Ran Reshef, Samuel Yamshon, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2024-209960

Published: 2024

Journal Articles

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Blood (2024) 144 (Supplement 1): 3381.1.

https://doi.org/10.1182/blood-2024-199411

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Sharmilee Nuli, Rajshekhar Chakraborty, Al-Ola Abdallah, Suzanne Lentzsch, Evguenia Ouchveridze, Douglas W Sborov, Amandeep Godara, Brian McClune, Ah-Reum Jeong, Samuel M. Rubinstein, Aaron Goodman, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2024-203731

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Jehad Almasri, Bashar Hasan, Zin Tarakji, Faris W. Naffa', Lynn Warner, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin, Samer Al Hadidi

Blood (2024) 144 (Supplement 1): 6986.

https://doi.org/10.1182/blood-2024-206645

Published: 2024

Journal Articles

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Michael Sang Hughes, Metodi Balev, Jai Radhakrishnan, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2024) 144 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2024-209301

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Caitlin Unkenholz, Mateo Mejia Saldarriaga, Esther Ortega, Jorge Monge, Christian A Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2024-210365

Published: 2024

Journal Articles

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Blood (2024) 144 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2024-206496

Published: 2024

Journal Articles

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Daniel T Peters, Jacob Amburn, Sascha Tuchman, Eben I Lichtman, Christopher Edward Jensen, Koyal Jain, Suzanne Lentzsch, Rajshekhar Chakraborty, Divaya Bhutani, Samuel M Rubinstein

Blood (2023) 142 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2023-189341

Published: 2023

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Utilization of Multiple Myeloma Treatments in Developing Countries: Systematic Review and Meta-Analysis

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only